Grunenthal GmbH - Strategic SWOT Analysis Review

Date: August 17, 2017
Pages: 35
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GD6EA62815FEN
Leaflet:

Download PDF Leaflet

Grunenthal GmbH - Strategic SWOT Analysis Review
Grunenthal GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights

Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. The company researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. It provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal focuses on discovering new methods to treat pain and developing new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Australia, Latin America and the US. It has production plants in Germany, Italy, Switzerland and Ecuador. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH Key Recent Developments

Jul 07,2017: Grünenthal Group: Launch of the Project - Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)
May 23,2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives - EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects
May 10,2017: Grünenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward
May 09,2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal
May 03,2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
SECTION 1 - ABOUT THE COMPANY

Grunenthal GmbH - Key Facts
Grunenthal GmbH - Key Employees
Grunenthal GmbH - Key Employee Biographies
Grunenthal GmbH - Major Products and Services
Grunenthal GmbH - History
Grunenthal GmbH - Company Statement
Grunenthal GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Grunenthal GmbH - Business Description
Grunenthal GmbH - Corporate Strategy
Grunenthal GmbH - SWOT Analysis
SWOT Analysis - Overview
Grunenthal GmbH - Strengths
Grunenthal GmbH - Weaknesses
Grunenthal GmbH - Opportunities
Grunenthal GmbH - Threats
Grunenthal GmbH - Key Competitors

SECTION 3 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Grunenthal GmbH, Recent Deals Summary

SECTION 4 – COMPANY’S RECENT DEVELOPMENTS

Jul 07, 2017: Grünenthal Group: Launch of the Project - Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET)
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients' Lives - EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects
May 10, 2017: Grünenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal
May 03, 2017: 23andMe and German Pain Specialist Grunenthal Explore the Genetics of Pain to Help Identify New Treatments for Patients
Oct 04, 2016: Gabriel Baertschi Takes Office as New CEO of Grunenthal Group as of October 1, 2016
Sep 27, 2016: A Research Consortium Under the Direction of Grunenthal Will Receive a Grant of €1.5 million From the European Fund for Regional Development and the Federal State of North Rhein-Westphalia
Jun 23, 2016: EFIC-Grunenthal Grant 2016
Jun 07, 2016: Grunenthal Appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer Effective October 1, 2016
Mar 03, 2016: Drug Discovery Collaboration between Grunenthal and Axxam

SECTION 5 – APPENDIX

Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Grunenthal GmbH, Key Facts
Grunenthal GmbH, Key Employees
Grunenthal GmbH, Key Employee Biographies
Grunenthal GmbH, Major Products and Services
Grunenthal GmbH, History
Grunenthal GmbH, Other Locations
Grunenthal GmbH, Subsidiaries
Grunenthal GmbH, Key Competitors
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Grunenthal GmbH, Recent Deals Summary

LIST OF FIGURES

Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

TAD Pharma GmbH
Purdue Pharma LP
Pensa Pharma GmbH
Mundipharma International Ltd
Mibe GmbH Arzneimittel
Endo Pharmaceuticals Inc
Skip to top


Nutricia GmbH - Strategic SWOT Analysis Review US$ 125.00 Feb, 2017 · 19 pages
VOCO GmbH - Strategic SWOT Analysis Review US$ 125.00 Jul, 2017 · 18 pages
TRACOE medical GmbH - Strategic SWOT Analysis Review US$ 125.00 Jun, 2017 · 19 pages

Ask Your Question

Grunenthal GmbH - Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: